| CHRNA2 rs2472553 | |||
---|---|---|---|---|
Patient groups | Success rate (%) | Â | ||
 | CC | CT | TT | P value |
Overall group (n = 737) | 44.7 | 47.5 | 46.2 | 0.81 |
Women (n = 395) | 40.6 | 41.2 | 71.4 | 0.26 |
Men (n = 342) | 49.4 | 54.5 | 16.7 | 0.19 |
CHRNA3 rs1051730 | ||||
Patient groups | Success rate (%) | Â | ||
 | CC | CT | TT | P value |
Overall group (n = 742) | 44.8 | 45.6 | 50.6 | 0.64 |
Women (n = 396) | 36.6 | 43.5 | 51.0 | 0.14 |
Men (n = 346) | 54.3 | 47.9 | 50.0 | 0.52 |
CHRNA5 rs16969968 | ||||
Patient groups | Success rate (%) | Â | ||
 | GG | GA | AA | P value |
Overall group (n = 731) | 43.0 | 46.6 | 54.3 | 0.18 |
Women (n = 389) | 35.7 | 44.0 | 56.3 | 0.03 |
Men (n = 342) | 52.0 | 49.1 | 51.5 | 0.87 |
CHRNA5 rs2036527 | ||||
Patient groups | Success rate (%) | Â | ||
 | GG | GA | AA | P value |
Overall group (n = 734) | 43.9 | 44.4 | 55.0 | 0.13 |
Women (n = 391) | 34.8 | 41.5 | 56.5 | 0.01 |
Men (n = 343) | 53.8 | 47.5 | 52.6 | 0.53 |
CHRNB3 rs6474413 | ||||
Patient groups | Success rate (%) | Â | ||
 | GG | GA | AA | P value |
Overall group (n = 727) | 46.0 | 46.0 | 45.9 | 1.00 |
Women (n = 388) | 41.7 | 44.4 | 39.5 | 0.64 |
Men (n = 339) | 51.9 | 47.8 | 52.8 | 0.67 |